Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Detalles Bibliográficos
Autores principales: Shimokihara, Kota, Kawahara, Takashi, Suzuki, Taisei, Mochizuki, Taku, Takamoto, Daiji, Teranishi, Jun‐ichi, Miyoshi, Yasuhide, Yumura, Yasushi, Yao, Masahiro, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799614/
https://www.ncbi.nlm.nih.gov/pubmed/29445483
http://dx.doi.org/10.1002/ccr3.1328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799614/
https://www.ncbi.nlm.nih.gov/pubmed/29445483
http://dx.doi.org/10.1002/ccr3.1328

Ejemplares similares